Gene transfer technologies and new gene therapy strategies
Gene therapy can treat inherited diseases by replacing a malfunctioning gene with a functional copy of it in the affected cells, or by editing the mutant sequence to the common version. Moreover, cells can be instructed to better fight acquired diseases such as cancer and infections. To achieve these ambitious goals, this unit has long been developing platforms for safe and efficient gene transfer, mostly based on modified viruses, and for targeted gene editing, based on artificial endonucleases (such as ZFNs and CRISPR/Cas). Group researchers then exploit these tools for genetic engineering hematopoietic stem cells (HSC) or lymphocytes ex vivo, or liver cells in vivo, always focusing on the goal of a future clinical translation of the strategy to treat disease.
Group's early work laid the foundation for the current broad use of lentiviral vectors (LV), both in biomedical research and as advanced therapy medicinal products in several gene therapy clinical trials, carried out in our own Institute and several other centers worldwide. To date, a few hundred patients suffering from immuno- hematopoietic or neurodegenerative disease, or some type of cancer, have markedly benefited from ex vivo HSC or T-cell gene therapy. As our early research has now reached the clinic, the unit has back at the bench working on the next generation genetic engineering.
Associated Research Unit: TARGETED CANCER GENE THERAPY
HSC gene therapy will become safer and broadly applicable if we could use novel strategies to engraft engineered cells without relying on chemotherapy, and perform more precise engineering. Group researchers pioneered and continue to develop gene targeting using artificial nucleases to edit gene sequences. These strategies offer radical new solutions to overcome the major hurdles that have long hindered progress of the gene therapy field. Gene correction, as opposed to gene replacement, not only restores the function of a disease gene but also its physiological expression control, while avoiding the risk of vector insertional mutagenesis. The unit is optimizing application of gene editing in T-cells and HSC for treating some primary immune deficiencies.
Concomitantly, to increase the efficacy and safety of gene editing, this unit is devising strategies to select and expand the edited cells before or after in vivo administration. Researchers has also developed a platform for liver-directed in vivo gene therapy, which ensures specific, robust and stable transgene expression in hepatocytes, and can induce or re-establish antigen-specific immune tolerance. The group has shown the efficacy and safety of this platform for the gene therapy of hemophilia in both small and large animal models. They are currently engineering new stealth vectors, which escape innate and adaptive immune recognition following systemic administration, assess gene transfer into liver stem/progenitor cells, and aim to bring LV-mediated liver gene therapy to first-in-human testing in severe hemophilia patients. Group studies may pave the way for broader application of the platform to other diseases, such as metabolic diseases and lysosomal storage diseases, which can benefit from efficient correction of hepatocytes defects.
Schiroli G, Ferrari S, Conway A, Jacob A, Capo V, Albano L, Plati T, Castiello MC, Sanvito F, Gennery AR, Bovolenta C, Palchaudhuri R, Scadden DT, Holmes MC, Villa A, Sitia G, Lombardo A, Genovese P*, Naldini L*. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci Transl Med. 2017 Oct 11;9(411). (* senior authorship)
Milani M, Annoni A, Bartolaccini S, Biffi M, Russo F, Di Tomaso T, Raimondi A, Lengler J, Holmes MC, Scheiflinger F, Lombardo A, Cantore A, Naldini L. Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy. EMBO Mol Med. 2017 Nov; 9(11): 1558–1573.
Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the firstmarketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017 Jun; 9 (6):737-740 23.
Amabile A, Migliara A, Capasso P, Biffi M, Cittaro D, Naldini L*, Lombardo A*. Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell 2016 Sep 22;167(1):219-232. (equal contribution * senior authorship)
Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. Science. 2016 Sep 9;353(6304):1101-2.
Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, Sergi LS, Gallina P, Benedicenti F, Bellinger D, Raymer R, Merricks E, Bellintani F, Martin S, Doglioni C, D'Angelo A, VandenDriessche T, Chuah MK, Schmidt M, Nichols T, Montini E, Naldini L. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med. 2015 Mar 4;7(277):277ra28.
Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A*, Naldini L*. Targeted genome editing in human repopulating hematopoietic stem cells. Nature 2014 Jun 12;510(7504):235-40. (equal contribution* senior authorship)
Biffi A*, Montini E*, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta N, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow David JD, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Therapeutic benefit in metachromatic leukodystrophy by lentiviral hematopoietic stem cell gene therapy. Science. 2013 Aug 23;341(6148): 1233158.
Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee P, Orange J, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. Lentivirus-based gene therapy of hematopoietic stem cells in Wiskott-Aldrich syndrome. Science. 2013 Aug 23; 341(6148): 1233151.
Provasi E*, Genovese P *, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory Philip D, Naldini L, Bonini C. Editing T cell specificity towards leukemia by zinc-finger nucleases and lentiviral gene transfer. Nature Medicine. 2012 May; 18(5):807-15.
Lombardo A, Cesana D*, Genovese P*, Di Stefano B*, Provasi E*, Colombo D*, Neri M, Magnani Z, Cantore A, Lo Riso P, Damo M, Muniz Pello O, Holmes MC, Gregory PD, Gritti A, Broccoli V, Bonini C, Naldini L. Site-specific integration and in situ tailoring of cassette design allow "sustainable" gene transfer. Nat Methods. 2011 Aug 21;8(10):861-9.
Gabriel R§, Lombardo A§, Arens A, Miller JC, Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, Holmes MG, Gregory PD, Glimm H, Schmidt M, Naldini L*, von Kalle C*. An unbiased genome-wide analysis of zinc finger nuclease specificity. Nat Biotechnol. 2011 Aug 7;29(9):816-23.
Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov F, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nature Biotechnology. 2007 Nov; 25(11):1298-306.
Brown BD*, Gentner B*, Cantore A, Colleoni S, Amendola M, Zingale A, Baccarini A, Lazzari G, Galli C, Naldini L. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nature Biotechnology. 2007 Dec;25(12):1457-1467. (*equal contribution)
Brown BD, Cantore A, Annoni A, Sergi Sergi L, Lombardo A, Della Valle P, D'Angelo A, Naldini L. A microRNA-regulated lentiviral vector mediates stable correction of Hemophilia B mice. Blood. Plenary paper 2007 Dec 15;110(13):4144-52.